Global Pharmaceutical CDMO Supply, Demand and Key Producers, 2026-2032

The global Pharmaceutical CDMO market size is expected to reach $ 270400 million by 2032, rising at a market growth of 7.5% CAGR during the forecast period (2026-2032).

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.

Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.

The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.

This report studies the global Pharmaceutical CDMO demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Pharmaceutical CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pharmaceutical CDMO that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Pharmaceutical CDMO total market, 2021-2032, (USD Million)

Global Pharmaceutical CDMO total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Pharmaceutical CDMO total market, key domestic companies, and share, (USD Million)

Global Pharmaceutical CDMO revenue by player, revenue and market share 2021-2026, (USD Million)

Global Pharmaceutical CDMO total market by Type, CAGR, 2021-2032, (USD Million)

Global Pharmaceutical CDMO total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Pharmaceutical CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Pharmaceutical CDMO market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Pharmaceutical CDMO Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Pharmaceutical CDMO Market, Segmentation by Type:
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO

Global Pharmaceutical CDMO Market, Segmentation by Application:
Pharmaceutical Company
Biotechnology Company
Other

Companies Profiled:
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL

Key Questions Answered

1. How big is the global Pharmaceutical CDMO market?

2. What is the demand of the global Pharmaceutical CDMO market?

3. What is the year over year growth of the global Pharmaceutical CDMO market?

4. What is the total value of the global Pharmaceutical CDMO market?

5. Who are the Major Players in the global Pharmaceutical CDMO market?

6. What are the growth factors driving the market demand? Show more